#long-acting injectables

ViiV Cabenuva injectable cabotegravir rilpivirine

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

FDA Lifts Clinical Hold on Long-Acting Lenacapavir

The injectable antiretroviral could potentially be taken once every six months for HIV treatment or PrEP.

Long-Acting Cabenuva Injections Now Approved for Teens

The long-acting regimen will enable some adolescents to take their HIV treatment just six times a year.

Injectable Cabenuva Can Now Be Started Without Oral Lead-In

People can now start Cabenuva injections directly without first taking cabotegravir and rilpivirine pills for a month.

Cabenuva Every Two Months Maintains Viral Suppression for Three Years

The every-other-month schedule of injectable cabotegravir plus rilpivirine enables some people to take HIV treatment just six times a year.

Long-Acting Lenacapavir Shows Continued Promise

The injectable antiretroviral could potentially be given once every six months for HIV treatment or prevention.

Cabenuva Now Approved for Every-Other-Month Dosing

Using the new dosing schedule, injectable cabotegravir and rilpivirine can be administered just six times a year.

Cabenuva Works Regardless of Weight

Long-acting injectable Cabenuva works well in people with obesity.

Apretude Approved—the First Long-Acting Injectable PrEP Option

Every-other-month cabotegravir injections may work even better than daily pills for HIV prevention.

Cabenuva Works Well Regardless of Body Weight

The long-acting injectable regimen suppressed HIV in more than 90% of study participants, including those with obesity.

POZ Focus - Different Treatments for Different Populations

This issue explores the latest choices in HIV regimens for various groups, including youth and older people.

Long-Acting Injectables and Older People

Here are considerations for long-term survivors thinking about switching HIV treatments.

Long-Acting Injectables and Younger People

Under 30? Here’s what to consider if you’re thinking about switching HIV treatments.

Making a Different Choice

Switching to a long-acting injectable was right on time for these three people living with HIV.

Treatment: Twice-Yearly

Lenacapavir, a twice-yearly injectable, suppresses viral load in people with highly resistant virus.

Prevention: Long-Acting PrEP

Long-acting injections given every two months could soon offer a new option for HIV pre-exposure prophylaxis.

Long-Acting Injectable PrEP Could Be Approved Early Next Year

Injections of cabotegravir given once every two months may work even better than daily pills for HIV prevention.

#long-acting injectables

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

FDA Lifts Clinical Hold on Long-Acting Lenacapavir

Long-Acting Cabenuva Injections Now Approved for Teens

Injectable Cabenuva Can Now Be Started Without Oral Lead-In

Cabenuva Every Two Months Maintains Viral Suppression for Three Years

Long-Acting Lenacapavir Shows Continued Promise

Cabenuva Now Approved for Every-Other-Month Dosing

Cabenuva Works Regardless of Weight

Apretude Approved—the First Long-Acting Injectable PrEP Option

Cabenuva Works Well Regardless of Body Weight

POZ Focus - Different Treatments for Different Populations

Long-Acting Injectables and Older People

Long-Acting Injectables and Younger People

Making a Different Choice

Treatment: Twice-Yearly

Prevention: Long-Acting PrEP

Long-Acting Injectable PrEP Could Be Approved Early Next Year

Science News

Ask POZ